TVRD צמיחת רווח למניה השנה Cara Corp

סמלים רשמיים של חברת Cara Corp (TVRD)

Cara Therapeutics Inc (TVRD) is expanding patient reach through oral drug formulations, overcoming clinical complexities. Analyzing the chart on GURU.Markets, we find that the annual EPS growth metric confirms the success of Korsuva in nephrology and physician loyalty to the scientific developments of Cara Therapeutics Inc (TVRD). The value 31.90 reflects the latest metric reading, capturing the issuer's yield dynamics.

צמיחת רווח נקי למניה השנה: Cara Therapeutics Inc (TVRD) עבור 04.07.2022 - 18.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור caratherapeutics.com (TVRD)

- ציטוטים ותחזית אנליסטים:
ניתוח בסיסי של החברה:Cara Pharma (TVRD)
מוצר עיקרי של Cara Therapeutics Inc

For Cara Therapeutics Inc (TVRD), the commercial success of KORSUVA directly determines the effectiveness of the business capitalization. This indicator captures the annual percentage change in net profit per share, reflecting the growth or decline rates of real shareholder income. By analyzing the EPS growth dynamics compared to last year, an investor can promptly detect a hidden slowdown in operational activity and reconcile financial results with market expectations.